Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Avalo Therapeutics to similar businesses based on the strength of its earnings, dividends, profitability, risk, analyst recommendations, valuation and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and price targets for Avalo Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalo Therapeutics | 1 | 2 | 11 | 0 | 2.71 |
| Avalo Therapeutics Competitors | 9874 | 15295 | 45659 | 1600 | 2.54 |
Avalo Therapeutics currently has a consensus target price of $36.82, indicating a potential upside of 374.46%. As a group, “Biotechnology” companies have a potential upside of 126.09%. Given Avalo Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than its peers.
Insider and Institutional Ownership
87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Avalo Therapeutics’ peers have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Valuation and Earnings
This table compares Avalo Therapeutics and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Avalo Therapeutics | $60,000.00 | -$78.26 million | -3.08 |
| Avalo Therapeutics Competitors | $703.08 million | $9.72 million | -18.76 |
Avalo Therapeutics’ peers have higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Avalo Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avalo Therapeutics | N/A | -34.21% | -29.84% |
| Avalo Therapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Summary
Avalo Therapeutics beats its peers on 8 of the 12 factors compared.
Avalo Therapeutics Company Profile
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
